

University of Groningen

## Addressing liver fibrosis by TRAIL targeted to hepatic stellate cells

Arabpour, Mohammad

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*  
2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Arabpour, M. (2016). *Addressing liver fibrosis by TRAIL targeted to hepatic stellate cells*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Propositions

Belonging to the PhD thesis

### **Addressing liver fibrosis by TRAIL targeted to hepatic stellate cells**

By Mohammad Arabpour

- 1: The inhibitory action of TRAIL on activated hepatic stellate cells makes it a promising drug candidate to counteract liver fibrosis.
  
- 2: The inhibitory action of TRAIL on activated hepatic stellate cells is achieved through inducing apoptosis and reducing the production of extra-cellular matrix elements.
  
- 3: The DR5 receptor-specific TRAIL variant is superior to either DR4 receptor-specific TRAIL or native TRAIL in eliminating activated hepatic stellate cells.
  
- 4: Targeting TRAIL via specific receptors increases the efficacy of the TRAIL-induced growth inhibition on activated hepatic stellate cells.
  
- 5: The combined use of Histone Acetyl Transferase (HAT) inhibitors and TRAIL enhances the killing efficiency of TRAIL in cancer cells.
  
- 6: Due to the controversial role of TRAIL in liver fibrosis, future applications of TRAIL in gene therapy of liver fibrosis is a matter of molecular refinement and precise targeting.